INTRODUCTION
Primary mediastinal large B-cell lymphoma (PMBL) is a distinct subtype of diffuse large B-cell lymphoma (DLBCL), accounting for 6%-10% of the cases. PMBL typically presents in women during the third to fourth decade of life. [1] However, its incidence in Saudi Arabia is yet unknown.
METHODS
A committee comprising experts in hematology and medical oncology was established under the supervision of the Saudi Lymphoma Group and in collaboration with the Saudi Oncology Society. For collecting evidence, a literature search was carried out with relevant keywords using online database search engines such as PubMed/Medline, Web of Science and Scopus. In addition, expert opinion was considered when necessary. The levels of evidence used in developing this guideline were as follows:
• Evidence level (EL)-1 (highest), evidence from Phase III randomized trials or meta-analyses • EL-2 (intermediate), evidence from well-designed Phase II trials or Phase III trials with limitations • EL-3 (low), evidence from retrospective or observational studies/reports and/or expert opinion.
This easy-to-follow grading system is convenient for readers to understand and allows an accurate assessment of the guideline's applicability in individual patients.
[2]
1. PATHOLOGIC DIAGNOSIS [5] [6] [7] 1.4. The tumor cells express B-cell antigens such as CD19, CD20, CD22, CD79a and CD45 and weak CD30 in >80% of cases. [1, 8, 9] These cells also frequently express other markers of Reed-Sternberg cells such as IRF4/MUM1. [10] Regarding the oncogenic abnormalities, a gain in chromosome 9p24 is seen in up to 75% of the cases. Immunoglobulin genes are rearranged but BCL-2, BCL-6 and MYC are rare or uncommon. [3, 9, 11] [13, 14] 3.3. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab) can be used for patients who wish to avoid radiation therapy, such as those aged <30 years and women with disease requiring irradiation of the breast tissue (EL-2) [15] 3.4. Management of patients with relapse is as follows: 3.4.1. Restaging is required including blood work, CT of neck and CAP as well as bone marrow biopsy 3.4.2. For all patients aged <60 years, management includes salvage chemotherapy with R-ESHAP (rituximab, etoposide, methylprednisolone, high-dose cytarabine and cisplatin) or R-GDP (rituximab, gemcitabine, dexamethasone and cisplatin) for a maximum of three cycles followed by high-dose chemotherapy and autologous stem cell transplant (EL-2) [16, 17] 3.4.3. Patients who are not transplant candidates could be treated with conventional chemotherapy, such as ESHAP and GDP, and with involved-field radiation therapy for symptomatic sites 3.4.4. Pembrolizumab can be used for patients who have relapsed after two or more prior lines of therapy (EL-3). [18] 4. FOLLOW UP (EL-3) 4.1. Every 3 months for 2 years, then every 6 months for 3 years, and then annually 4.2. History and physical examination should be documented in every visit 4.3. CBC with differential count, erythrocyte sedimentation rate and liver function test should be requested in every visit 4.4. Thyroid-stimulating hormone test should be carried out at least once annually if the patient had received radiotherapy to the neck 4.5. CT of neck and CAP is required every 6-12 months for first 2 years, and then based on the clinical presentation 4.6. Chest X-ray should be performed at each visit in the first 2 years, and then every other visit, especially for patients who previously had intrathoracic disease 4.7. Mammogram is required who received chest radiotherapy, beginning 10 years after diagnosis of lymphoma or when aged 40 years, whichever comes first 4.8. Annual influenza immunization is recommended. [19] Financial support and sponsorship Nil.
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